[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"side-effect-of-drug\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:side-effect-of-drug":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100540853","phase-2-pharmacogenetic-panel-to-prevent-adverse-drug-reactions-in-daily-primary-care-practice-100540853",false,"NCT06322238","Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:","A Multi-gene Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice: Open-label, Mayo Clinic Multisite (Mayo Clinic Health System-Rochester Primary Care), Controlled, Implementation Study Taking the Results of the PREPARE Study Into Minnesota (PREPARE-Mayo)","PREPARE-Mayo","Inclusion Criteria:\n\n* Inclusion Criteria:\n\nIn order to be eligible to participate in this study, a subject must meet all of the following criteria:\n\n1. Subject must be ≥ 18 years old\n2. Subject must receive a 1st prescription (meaning no known prescription for this drug in the preceding 12 months) for a drug included in Table 1, which is prescribed to them in routine primary care.\n3. Subject is able and willing to take part and willing to be followed up on for 48 weeks\n4. Subject is able to donate saliva\n5. Subject has signed informed consent\n6. Subject meets requirement for computer access implying computer literacy as measured by active use of the patient portal or their email\n\nExclusion Criteria:\n\n1. For the investigational arm only: Previous (direct-to-consumer, or clinical) pharmacogenomic testing that includes any of the genes included in the Focused Pharmacogenomics Panel\n2. Pregnant or lactating (to be verbally confirmed with the patient)\n3. Life expectancy estimated to be less than three months as determined by patient receiving hospice care\n4. Duration of index drug total treatment length is planned to be less than seven consecutive days.\n5. Current inpatients\n6. Unable to consent to the study\n7. Unwilling to take part\n8. Subject has no permanent address\n9. Subject has no current primary care provider\n10. Subject is, in the opinion of the study coordinator after discussion with participating clinician\u002Fpharmacist\u002Finvestigator, not suitable to participate in the study\n11. Patient has a diagnosis of stage 4 or 5 chronic kidney disease (CKD) or is receiving dialysis\n12. Patients with advanced liver failure (stage Child-Pugh C) or a diagnosis of liver cirrhosis\n13. History of a liver transplant or an allogeneic hematopoietic stem cell transplant\n14. DNA sample collected that requires retesting in the event that DNA collected was not sufficient for testing as determined by the laboratory",true,"ALL","18 Years",{"count":21,"type":22},66,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The purpose of this study is to determine whether the implementation of pre-emptive pharmacogenomic (PGx) testing of a panel of clinically relevant PGx markers, to guide the dose and drug selection for 39 commonly prescribed drugs, will result in an overall reduction in the number of clinically relevant drug-genotype associated ADRs which are causally related to the initial drug of inclusion (referred to as 'index drug').",[28,29,30,31,32],"Pharmacogenomic Drug Interaction","Side Effect of Drug","Ineffective Drug Action","Drug Metabolism, Poor, CYP2D6-Related","Drug Metabolism, Poor, CYP2C19-Related",[34,35,36,37,38,39,40,15],"pharmacogenomics","PGx","CPIC","primary care","drug metabolism","side effects","ineffectiveness","RECRUITING","2025-10-10",{"date":44,"type":45},"2025-10-14","ACTUAL",{"date":47,"type":45},"2024-12-01",{"date":49,"type":22},"2027-04",{"name":51,"class":52},"Mayo Clinic","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":53},"100498835","comparison-of-chemoradiotherapy-and-chemoradiotherapy-combined-with-consolidation-chemotherapy-for-escc-100498835","NCT05775419","Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC","A Prospective Randomized Controlled Clinical Study Comparing Curative Effect of Non-surgical Esophageal Squamous Cell Carcinoma With Radical Chemoradiotherapy and Radical Chemoradiotherapy Combined With Consolidation Chemotherapy","Inclusion Criteria:\n\n1. Age 18-70 years old, not limited to male or female; at least able to take liquid diet;\n2. Esophageal squamous cell carcinoma proved by histopathology;\n3. Esophageal squamous cell carcinoma that is inoperable or refuses surgery,\n4. According to the 2017 8th edition of AJCC esophageal cancer new staging criteria, the tumor is T2N0M0-TxNxM0 stage;\n5. ECOG 0-1; life expectancy \\> 6 months;\n6. No chemotherapy was used before selection;\n7. No history of radiotherapy;\n8. No surgical treatment;\n9. No serious allergic history;\n10. Hemoglobin 100 g\u002FL, WBC3.5109\u002FL, neutrophils 1.5109, platelets 100109\u002FL; CR1.5 upper limit of normal, TB2.5 upper limit of normal, AST and ALT2.5 upper normal limit, AKP2.5 upper normal limit ; Be able to understand the research and have signed the informed consent;\n\nExclusion Criteria:\n\n1. History of malignant tumors in other parts;\n2. Duplicate carcinoma of the esophagus;\n3. Pregnant or lactating patients;\n4. Fertility but not using contraceptive measures;\n5. Serious comorbidities: very high-risk hypertension, severe pulmonary function impairment, massive myocardial infarction, cardiac function ≥ grade II, mental history and severe diabetes;\n6. During the active period of infectious diseases;\n7. Participate in other clinical trials at present or within four weeks before enrollment;\n8. Simultaneous treatment with other anti-cancer drugs (including anti-cancer traditional Chinese medicine);\n9. After esophageal stent placement;\n10. Cases with perforation tendency;\n11. Have a history of organ transplantation.\n12. Widespread metastases throughout the body, including lung, liver, bone, and intracranial metastases;\n13. Known or suspected allergic to chemotherapy drugs; According to the judgment of the investigator, there are concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study.","70 Years",{"count":63,"type":22},1216,[65],"NA","This study is a phase III, multicenter, prospective randomized controlled clinical study comparing the efficacy of non-surgical esophageal squamous cell carcinoma with radical chemoradiotherapy and radical chemoradiotherapy combined with consolidation chemotherapy. The survival time and side effects of patients were observed and compared.",[68,69,29],"Esophageal Squamous Cell Carcinoma","Chemotherapy Effect","2023-03-16",{"date":72,"type":45},"2023-03-20",{"date":74,"type":45},"2021-06-30",{"date":76,"type":22},"2028-06-30",{"name":78,"class":52},"The First Affiliated Hospital with Nanjing Medical University"]